Kay-Won Chang, MD
Cardiovascular Disease (Cardiology) · Dublin
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
Offices
8 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Washington Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chang’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A144085 · Current
Licensed to practise in California · since 2016 · expires 2028-05-31 · University of Texas Medical School at Houston.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$177,938
Medicare paid this office $177,938 for 983 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 283 | $51,304 | $181 |
| Long return visit (40+ min) | 181 | $49,004 | $164 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 57 | $12,918 | $227 |
| New patient visit (60+ min) | 51 | $10,037 | $197 |
| Return visit (30+ min) | 68 | $9,367 | $106 |
See all 24 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 283 | $51,304 | $181 |
| Long return visit (40+ min) | 181 | $49,004 | $164 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 57 | $12,918 | $227 |
| New patient visit (60+ min) | 51 | $10,037 | $197 |
| Return visit (30+ min) | 68 | $9,367 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $6,676 | $101 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $4,954 | $450 |
| Heart muscle strain imaging | 105 | $4,167 | $39 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 289 | $3,460 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 56 | $3,405 | $60 |
| New patient visit (45+ min) | 29 | $3,396 | $117 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 151 | $3,036 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,909 | $139 |
| Ultrasound of heart, follow-up | 18 | $2,298 | $104 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 87 | $1,989 | $22 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,271 | $67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 18 | $1,157 | $64 |
| Heart rhythm recording of continous external ekg over 8-15 days | 85 | $1,079 | $12 |
| Injection, perflutren lipid microspheres, per ml | 24 | $1,053 | $33 |
| 3d radiographic procedure | 40 | $1,049 | $26 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $508 | $25 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 12 | $436 | $36 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $395 | $26 |
| Injection, regadenoson, 0.1 mg | 14 | $267 | None |
Who their Medicare patients are
983 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 18% · Women 55% · Also on Medicaid 18% · Health risk score 1.21. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Diabetes 33% · Chronic kidney disease 28% · Atrial fibrillation 28% · Heart failure 23% · Cancer 16% · Depression 14% · COPD 10% · Dementia 8% · Stroke 6%.
The office billed $836,203, Medicare allowed $239,848 and paid $177,938; for 2,090 services of 39 kinds; $1,337 of it was for drugs given in the office and $176,601 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 983 | 2,090 | 77 | 1.21 | $836,203 | $177,938 |
| 2023 | 975 | 2,110 | 76 | 1.18 | $793,065 | $173,223 |
| 2022 | 568 | 1,216 | 76 | 1.30 | $535,317 | $125,031 |
| 2021 | 47 | 96 | 75 | 0.97 | $39,690 | $12,625 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 252 | $48,373 | $190 |
| Return visit (30+ min) | 146 | $30,729 | $116 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 52 | $11,983 | $230 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 22 | $10,057 | $457 |
| Long return visit (40+ min) | 47 | $10,038 | $170 |
| New patient visit (45+ min) | 69 | $9,451 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $8,705 | $106 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 358 | $5,309 | $14 |
| New patient visit (60+ min) | 27 | $5,007 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,328 | $144 |
| Injection, regadenoson, 0.1 mg | 25 | $4,248 | None |
| Heart muscle strain imaging | 88 | $3,515 | $39 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $2,875 | $62 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 18 | $2,845 | $158 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 97 | $2,282 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 37 | $2,219 | $58 |
| Injection, perflutren lipid microspheres, per ml | 24 | $1,724 | $36 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 23 | $1,437 | $62 |
| Heart rhythm recording of continous external ekg over 8-15 days | 96 | $1,228 | $13 |
| 3d radiographic procedure | 39 | $1,017 | $25 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 20 | $573 | $15 |
| Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | 13 | $492 | $38 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $435 | $26 |
2022: 17 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 167 | $32,764 | $195 |
| Return visit (30+ min) | 112 | $22,529 | $113 |
| New patient visit (45+ min) | 80 | $10,998 | $137 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 29 | $6,699 | $231 |
| Long return visit (40+ min) | 34 | $6,047 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $5,511 | $90 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 22 | $4,046 | $184 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,830 | $174 |
| Heart muscle strain imaging | 89 | $3,474 | $39 |
| New patient visit (60+ min) | 16 | $3,093 | $193 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 42 | $2,823 | $67 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 40 | $2,559 | $62 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 80 | $1,950 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 22 | $1,279 | $58 |
| Injection, perflutren lipid microspheres, per ml | 18 | $1,260 | $36 |
| Heart rhythm recording of continous external ekg over 8-15 days | 78 | $1,137 | $14 |
| 3d radiographic procedure | 42 | $982 | $23 |
2021: 4 services
| Return visit (30+ min) | 21 | $2,942 | $123 |
| Long return visit (40+ min) | 13 | $2,827 | $166 |
| New patient visit (60+ min) | 11 | $2,270 | $206 |
| New patient visit (45+ min) | 14 | $2,195 | $157 |
Drugs they prescribed that Part D paid
$379,826
Pharmacies billed $379,826 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,279) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
988 generic and 291 brand-name prescriptions · $379,826 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 158 | $209,566 | $1,326 |
| Entresto | 40 | $41,767 | $1,044 |
| Jardiance | 26 | $26,314 | $1,012 |
| Repatha Sureclick | 16 | $22,339 | $1,396 |
| Xarelto | 13 | $21,368 | $1,644 |
See all 18 drugs
| Eliquis | 158 | $209,566 | $1,326 |
| Entresto | 40 | $41,767 | $1,044 |
| Jardiance | 26 | $26,314 | $1,012 |
| Repatha Sureclick | 16 | $22,339 | $1,396 |
| Xarelto | 13 | $21,368 | $1,644 |
| Praluent | 12 | $13,278 | $1,106 |
| Rosuvastatin | 372 | $6,381 | $17 |
| Atorvastatin | 209 | $1,818 | $9 |
| Ezetimibe | 49 | $1,649 | $34 |
| Metoprolol | 76 | $854 | $11 |
| Diltiazem 24hr Er (Cd) | 11 | $634 | $58 |
| Telmisartan | 26 | $558 | $21 |
| Carvedilol | 35 | $336 | $10 |
| Amlodipine Besylate | 38 | $211 | $6 |
| Lisinopril | 11 | $129 | $12 |
| Metoprolol | 21 | $101 | $5 |
| Furosemide | 32 | $85 | $3 |
| Clopidogrel | 16 | $72 | $5 |
Year by year
| 2024 | 1,279 | 257 | 0% (0) | 23% | $379,826 |
| 2023 | 957 | 212 | 0% (0) | None | $302,957 |
| 2022 | 641 | 142 | 0% (0) | 20% | $162,641 |
| 2021 | 266 | 64 | 0% (0) | 24% | $52,418 |
| 2020 | 180 | 46 | 0% (0) | 23% | $16,805 |
| 2019 | 168 | 41 | 0% (0) | 23% | $27,623 |
| 2018 | 174 | 47 | None | None | $16,697 |
| 2017 | 124 | 48 | None | None | $10,089 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Eliquis | 74 | $108,415 | $1,465 |
| Entresto | 41 | $66,129 | $1,613 |
| Jardiance | 34 | $55,627 | $1,636 |
| Xarelto | 14 | $22,209 | $1,586 |
| Repatha Pushtronex | 12 | $14,252 | $1,188 |
| Rosuvastatin | 260 | $8,482 | $33 |
| Atorvastatin | 141 | $2,735 | $19 |
| Telmisartan | 24 | $1,650 | $69 |
| Ezetimibe | 31 | $1,523 | $49 |
| Metoprolol | 65 | $1,223 | $19 |
| Carvedilol | 42 | $772 | $18 |
| Chlorthalidone | 21 | $578 | $28 |
| Amlodipine Besylate | 42 | $531 | $13 |
| Clopidogrel | 12 | $400 | $33 |
| Furosemide | 30 | $233 | $8 |
| Metoprolol | 15 | $214 | $14 |
| Spironolactone | 13 | $194 | $15 |
2022: 14 drugs
| Eliquis | 47 | $51,338 | $1,092 |
| Jardiance | 34 | $39,729 | $1,169 |
| Entresto | 33 | $39,456 | $1,196 |
| Rosuvastatin | 111 | $4,078 | $37 |
| Telmisartan | 27 | $1,843 | $68 |
| Atorvastatin | 84 | $1,278 | $15 |
| Metoprolol | 57 | $1,141 | $20 |
| Ezetimibe | 15 | $980 | $65 |
| Chlorthalidone | 24 | $768 | $32 |
| Carvedilol | 37 | $472 | $13 |
| Metoprolol | 16 | $396 | $25 |
| Amlodipine Besylate | 24 | $241 | $10 |
| Spironolactone | 16 | $172 | $11 |
| Furosemide | 31 | $168 | $5 |
2021: 5 drugs
| Pradaxa | 17 | $8,438 | $496 |
| Atorvastatin | 39 | $692 | $18 |
| Rosuvastatin | 29 | $669 | $23 |
| Metoprolol | 15 | $437 | $29 |
| Furosemide | 22 | $139 | $6 |
2020: 5 drugs
| Pradaxa | 20 | $9,183 | $459 |
| Atorvastatin | 29 | $674 | $23 |
| Bisoprolol | 14 | $574 | $41 |
| Metoprolol | 15 | $345 | $23 |
| Carvedilol | 11 | $128 | $12 |
2019: 4 drugs
| Atorvastatin | 26 | $524 | $20 |
| Clopidogrel | 20 | $408 | $20 |
| Spironolactone | 16 | $200 | $12 |
| Furosemide | 13 | $163 | $13 |
2018: 1 drug
| Atorvastatin | 20 | $376 | $19 |
2017: 2 drugs
| Lantus | 11 | $2,759 | $251 |
| Atorvastatin | 12 | $113 | $9 |
Professional record
- NPI
- 1205213410
- Licence
- CA A144085California A144085: Current · expires 2028-05-31
- Trained
- University of Texas Medical School at Houston, 2015
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 3200 Kearney Street, Building 2, 1st Floor, Fremont, CA, 94538
- NPI first listed
- 2015-04-27
- NPI last updated
- 2021-08-25
- NPI record certified
- 2021-06-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3200 Kearney Street, Fremont, CA, 94538